In the NRG Oncology clinical trial NRG-RTOG 1112, which sought to better determine the role of stereotactic body radiation therapy (SBRT) in the treatment of patients with advanced hepatocellular carcinoma, it was demonstrated that adding SBRT to Sorafenib improved overall survival. These results were presented during the Plenary Session of the American Society for Radiation Oncology’s Annual Meeting in October 2022. NRG Oncology designed and led this trial which was conducted in the National Clinical Trials Network with funding from the National Cancer Institute, part of the National Institutes of Health.